Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Immix Biopharma (NASDAQ:IMMX) had its target price lifted by analysts at Mizuho from $14.00 to $15.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 80.27% from the company’s current price.

IMMX has been the topic of a number of other reports. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Morgan Stanley began coverage on Immix Biopharma in a research note on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target on the stock. Citizens Jmp reiterated a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a report on Friday. Finally, HC Wainwright boosted their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a report on Friday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.25.

Immix Biopharma Stock Performance

Shares of IMMX stock traded up $0.17 on Monday, hitting $8.32. 116,583 shares of the stock traded hands, compared to its average volume of 874,850. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $11.61. The firm’s 50-day moving average price is $7.77 and its two-hundred day moving average price is $5.28. The stock has a market capitalization of $440.76 million, a PE ratio of -9.38 and a beta of 0.25.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Wednesday, March 25th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). On average, equities research analysts anticipate that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Immix Biopharma

Several institutional investors have recently bought and sold shares of IMMX. Allworth Financial LP acquired a new stake in Immix Biopharma during the 4th quarter worth approximately $30,000. Velan Capital Investment Management LP purchased a new stake in Immix Biopharma in the second quarter valued at $52,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at about $56,000. Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma during the fourth quarter worth approximately $67,000. Finally, Kera Capital Partners Inc. acquired a new position in shares of Immix Biopharma in the 4th quarter valued at $68,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.